Hennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)

Hennion & Walsh Asset Management Inc. raised its position in ProKidney Corp. (NASDAQ:PROK - Free Report) by 48.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 844,277 shares of the company's stock after purchasing an additional 275,630 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.29% of ProKidney worth $740,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of ProKidney by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,231,930 shares of the company's stock valued at $3,773,000 after acquiring an additional 27,996 shares in the last quarter. Bleichroeder LP boosted its holdings in shares of ProKidney by 8.4% in the fourth quarter. Bleichroeder LP now owns 2,000,000 shares of the company's stock valued at $3,380,000 after acquiring an additional 155,000 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of ProKidney by 7.4% in the fourth quarter. Northern Trust Corp now owns 890,907 shares of the company's stock valued at $1,506,000 after acquiring an additional 61,206 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of ProKidney by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 759,787 shares of the company's stock valued at $1,284,000 after acquiring an additional 10,069 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of ProKidney by 3.2% in the fourth quarter. Bank of America Corp DE now owns 539,232 shares of the company's stock valued at $911,000 after acquiring an additional 16,538 shares in the last quarter. Institutional investors and hedge funds own 51.59% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of ProKidney from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Insider Buying and Selling

In other ProKidney news, insider Control Empresarial De Capital bought 1,032,218 shares of ProKidney stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average cost of $0.61 per share, for a total transaction of $629,652.98. Following the completion of the acquisition, the insider now owns 72,592,325 shares of the company's stock, valued at approximately $44,281,318.25. This represents a 1.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders acquired 1,787,716 shares of company stock worth $1,175,419. Corporate insiders own 41.49% of the company's stock.

ProKidney Price Performance

Shares of ProKidney stock traded down $0.07 on Wednesday, hitting $0.93. The company had a trading volume of 383,885 shares, compared to its average volume of 655,349. The business has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $1.25. The company has a market cap of $273.64 million, a PE ratio of -1.70 and a beta of 1.36. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $3.39.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter. On average, equities research analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.